# A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants

> **NCT01309386** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 100 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Tapentadol ER
- **DRUG:** Morphine SR

## Key facts

- **NCT ID:** NCT01309386
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2013-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01309386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01309386, "A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01309386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*